Sentinel Lymph Node imaging using SPECT/CT imaging before and after treatment with chemoradiotherapy in patients with cancer of the oesophagus or gastro-oesophageal junction
Not Applicable
Completed
- Conditions
- Oesophageal cancer
- Registration Number
- ACTRN12618001433291
- Lead Sponsor
- Karolinska University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does SPECT/CT imaging reveal about sentinel lymph node metastasis in oesophageal cancer?
How does neoadjuvant chemoradiotherapy affect sentinel lymph node detection accuracy using SPECT/CT in gastro-oesophageal junction cancer?
Which biomarkers correlate with sentinel lymph node imaging outcomes in ACTRN12618001433291 oesophageal cancer trial?
What adverse events are associated with sequential SPECT/CT lymphoscintigraphy in oesophageal cancer patients undergoing chemoradiotherapy?
How does SPECT/CT sentinel lymph node imaging compare to conventional methods in staging gastro-oesophageal junction adenocarcinoma?